Livforsakringsbolaget Skandia Omsesidigt Boosts Stock Position in Bristol-Myers Squibb (NYSE:BMY)

Livforsakringsbolaget Skandia Omsesidigt raised its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 1.9% in the 4th quarter, Holdings Channel reports. The fund owned 107,068 shares of the biopharmaceutical company’s stock after acquiring an additional 1,962 shares during the quarter. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Bristol-Myers Squibb were worth $5,490,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. OFI Invest Asset Management acquired a new position in Bristol-Myers Squibb during the 3rd quarter worth approximately $25,000. True Wealth Design LLC acquired a new position in Bristol-Myers Squibb during the 4th quarter worth approximately $26,000. Milestone Investment Advisors LLC acquired a new position in Bristol-Myers Squibb during the 3rd quarter worth approximately $27,000. Coppell Advisory Solutions LLC acquired a new position in Bristol-Myers Squibb during the 2nd quarter worth approximately $28,000. Finally, Blue Bell Private Wealth Management LLC increased its position in Bristol-Myers Squibb by 61.5% during the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 200 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol-Myers Squibb Trading Down 0.9 %

Shares of Bristol-Myers Squibb stock traded down $0.43 during trading hours on Wednesday, reaching $47.83. 11,759,869 shares of the company’s stock were exchanged, compared to its average volume of 15,847,523. Bristol-Myers Squibb has a 52-week low of $47.58 and a 52-week high of $70.93. The firm has a market capitalization of $96.94 billion, a price-to-earnings ratio of 12.50, a price-to-earnings-growth ratio of 1.46 and a beta of 0.39. The company has a fifty day moving average of $51.27 and a 200-day moving average of $51.62. The company has a current ratio of 1.43, a quick ratio of 1.31 and a debt-to-equity ratio of 1.24.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.55 by $0.15. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. The company had revenue of $11.48 billion for the quarter, compared to analyst estimates of $11.19 billion. During the same quarter in the prior year, the company posted $1.82 EPS. The business’s revenue for the quarter was up .6% compared to the same quarter last year. Sell-side analysts forecast that Bristol-Myers Squibb will post 6.63 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be given a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 5.02%. The ex-dividend date of this dividend is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 62.18%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on BMY shares. Wells Fargo & Company lowered their price target on Bristol-Myers Squibb from $58.00 to $51.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 6th. Redburn Atlantic cut Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $77.00 to $54.00 in a report on Tuesday, February 6th. StockNews.com cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Monday. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. Finally, Societe Generale cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $61.12.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.